Summary
The provided AI claims about aspirin overdose signs/symptoms and dosing thresholds are largely not supported or contradicted by the supplied FDA label excerpts; the label excerpts do not provide overdose symptom timing, specific overdose symptom lists, or dose-threshold specifics for serious complications/stomach ulcers/bleeding. Major portions are therefore unsupported relative to the provided label.
Category Scores
Accurate Statements
Unsupported Statements
Aspirin overdose occurs when an individual takes more than the recommended dose of aspirin.
The supplied label excerpts do not define aspirin overdose or criteria based on 'recommended dose.'
Aspirin overdose can cause nausea.
The supplied label excerpts list GI side effects during therapy (stomach pain, heartburn, nausea, vomiting, gross GI bleeding), but do not provide overdose-specific symptom statements.
Aspirin overdose can cause vomiting.
No overdose-specific symptom information is provided in the supplied excerpts.
Aspirin overdose can cause stomach pain.
GI side effects are described for therapy, but overdose-specific symptom statements are not provided.
Taking more than 1,000 milligrams of aspirin per day can lead to serious health complications.
No dose threshold (e.g., >1,000 mg/day) or overdose threshold is provided in the supplied label excerpts.
Taking more than 1,000 milligrams of aspirin per day can lead to stomach ulcers.
The supplied label warns physicians to remain alert for signs of ulceration/bleeding, but does not provide a >1,000 mg/day threshold nor link that threshold to stomach ulcers.
Taking more than 1,000 milligrams of aspirin per day can lead to bleeding.
The label describes increased bleeding risk with aspirin (and general bleeding risk factors), but does not specify a >1,000 mg/day threshold.
Increasing the dose of aspirin can increase the risk of cardiovascular problems.
The supplied label excerpt does not describe a dose-response relationship between aspirin dose increases and cardiovascular problems.
Increasing the dose of aspirin can increase the risk of heart attack.
No label excerpt provided supports this claim.
Increasing the dose of aspirin can increase the risk of stroke.
The supplied label indicates this product reduces risk of stroke; no excerpt supports this claim.
Symptoms of aspirin overdose can start to appear within 30 minutes to 1 hour after taking the excess dose.
No overdose symptom onset timing is provided in the supplied label excerpts.
Aspirin overdose can cause stomach upset leading to nausea and vomiting.
The label describes GI side effects during therapy, but provides no overdose-specific 'stomach upset leading to...' statement.
Excessive aspirin use can cause stomach pain.
The supplied label supports stomach pain as a GI side effect of therapy, but does not explicitly state 'excessive use' or connect that phrase to overdose.
Aspirin overdose can cause dizziness.
No overdose symptom 'dizziness' is provided in the supplied excerpts.
Aspirin overdose can cause lightheadedness.
No overdose symptom 'lightheadedness' is provided in the supplied excerpts.
Aspirin overdose can cause dizziness and lightheadedness due to a drop in blood pressure.
The label warns hypotension can be exacerbated by dipyridamole (not an overdose mechanism statement), and does not provide overdose-specific dizziness/lightheadedness due to blood pressure drop.
An increased heart rate can occur due to the stimulant effects of aspirin in aspirin overdose.
The supplied label excerpts do not describe stimulant effects of aspirin or overdose-related tachycardia.
Aspirin overdose can cause confusion.
No overdose symptom 'confusion' is provided in the supplied excerpts.
Aspirin overdose can cause disorientation.
No overdose symptom 'disorientation' is provided in the supplied excerpts.
Aspirin overdose is a serious medical emergency.
The supplied label excerpt includes an 'overdosage' section but does not state that overdose is a 'serious medical emergency.'
Contradictions
Low
AI Statement
Increasing the dose of aspirin can increase the risk of stroke.
Label Reference
1 INDICATIONS AND USAGE / 14 CLINICAL STUDIES: 'indicated to reduce the risk of stroke' and ESPS2 results showing stroke risk reduction.
Important Omissions
Any label-supported overdose assessment/management details (e.g., specific treatment steps) corresponding to the overdose claims.
Importance:
Moderate
Label-supported specifics that overdosage of aspirin/dipyridamole is likely dominated by dipyridamole signs/symptoms due to dose ratio.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
High
Multiple overdose-specific symptom statements and onset timing/dose-threshold assertions are unsupported by the provided label excerpts. While the label does acknowledge GI bleeding risks and provides general overdosage framing, unsupported overdose details could mislead interpretation of toxicity timing/severity.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
Overdose-related claims (symptom list, onset timing, and numeric dose threshold) are not supported by the supplied FDA label excerpts for aspirin and extended-release dipyridamole capsules.
Suggested Improvement
Replace overdose-specific symptom/onset/treshold claims with statements directly supported by the provided label excerpts (e.g., product indication, GI side effects during therapy, bleeding risk warning, and the label’s overdosage note that signs/symptoms are likely dominated by dipyridamole due to dose ratio). Avoid numeric thresholds and timing not present in the label excerpts.